Tg Therapeutics: MACD Death Cross, KDJ Death Cross on 15min Chart Triggered

According to the 15-minute chart for Tg Therapeutics, the MACD Death Cross and KDJ Death Cross indicators have been triggered at 09:45 on 12 September 2025. This suggests that the stock price has the potential to continue declining, with a shift in momentum towards the downside and a further decrease in value.

Tg Therapeutics, Inc. (NASDAQ: TGTX) stock has shown signs of potential decline, as indicated by the triggering of both the MACD Death Cross and KDJ Death Cross indicators at 09:45 on September 12, 2025 TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment^[1]. These technical indicators suggest a shift in momentum towards the downside, which could lead to further depreciation in the stock price.

The MACD (Moving Average Convergence Divergence) Death Cross occurs when the MACD line crosses below the signal line, typically indicating a bearish trend. The KDJ (Kaufman Adaptive Moving Average) Death Cross, on the other hand, is triggered when the KDJ line crosses below the J line, also signaling a potential downtrend. Both indicators have been historically reliable in predicting changes in stock momentum.

Tg Therapeutics recently announced the commencement of a Phase 3 trial for its subcutaneous BRIUMVI, an anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS) . The trial aims to evaluate the pharmacokinetics, pharmacodynamics, safety, and clinical effects of subcutaneous BRIUMVI compared to the currently approved intravenous (IV) version. If successful, this could broaden the market opportunity for BRIUMVI, potentially reaching an estimated 40% of the RMS CD20 dynamic market that opts for self-injectable CD20 therapies.

Despite this promising development, the stock's technical indicators suggest a cautious approach for investors. The MACD and KDJ Death Crosses indicate a potential shift in market sentiment, which could be influenced by various factors including market conditions, geopolitical events, and investor sentiment.

Investors should closely monitor the stock's performance and the progress of the Phase 3 trial to make informed decisions. The trial's outcome could significantly impact the stock's future trajectory, and any positive results could potentially reverse the current downward trend.